

**Title:** Adenovirus (AdV) Infections Among Pediatric Hematopoietic Stem Cell Transplant (HSCT) Patients in the United States: Epidemiology, Management, and Outcomes

**UPDATED:** 11/21/2019

**FDA is seeking to fill key data gaps in our knowledge of the epidemiology and current management of adenovirus (AdV) infections among pediatric hematopoietic stem cell transplant (HSCT) recipients in the United States. The ultimate goal of this research is to facilitate development of novel antiviral agents to treat adenovirus infections in this population (FDABAA-20-00123, Research Area 5.2.12).**

#### **Funding**

FDA has allocated \$350,000 to fund research in this area in FY2020. The study period will be 2 years. The contractor will be responsible for subcontracting with collaborating institutions.

#### **Timelines**

Stage 1 Responses (Quad Chart and White Paper) will be accepted until **December 15, 2019**.

#### **How to Submit a Response**

- Submit Stage 1 responses (Quad Chart and White Paper) with reference to the above BAA number and research area of interest 5.2.12.
- The BAA document provides detailed instructions for potential offerors. Please see pages 32-50. [https://beta.sam.gov/opp/2313b4c8ab7a967d880cf16dee4ec116/view?keywords=fdabaa-20-00123&sort=-relevance&index=&is\\_active=true&page=1](https://beta.sam.gov/opp/2313b4c8ab7a967d880cf16dee4ec116/view?keywords=fdabaa-20-00123&sort=-relevance&index=&is_active=true&page=1) (Updated Link)